Cargando…

Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells

Chronic liver inflammation can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Kupffer cells (KC) secrete proinflammatory and fibrogenic cytokines in response to lipopolysaccharide (LPS), and so play an important role in liver inflammation, where they induce hepatocellular damage. LPS als...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Hye-Young, Lee, So-Hee, Han, Eugene, Hwang, Jae Seok, Han, Sol, Kim, Mi Kyung, Jang, Byoung Kuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569597/ https://www.ncbi.nlm.nih.gov/pubmed/36232933 http://dx.doi.org/10.3390/ijms231911636

Ejemplares similares

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

Increased Levels of Phosphorylated ERK Induce CTGF Expression in Autophagy-Deficient Mouse Hepatocytes
por: Seo, Hye-Young, et al.
Publicado: (2022)

The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain
por: Cho, Pyung Goo, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

Kahweol Ameliorates the Liver Inflammation through the Inhibition of NF-κB and STAT3 Activation in Primary Kupffer Cells and Primary Hepatocytes
por: Seo, Hye-Young, et al.
Publicado: (2018)

Kahweol activates the Nrf2/HO-1 pathway by decreasing Keap1 expression independently of p62 and autophagy pathways
por: Seo, Hye-Young, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Kahweol decreases hepatic fibrosis by inhibiting the expression of connective tissue growth factor via the transforming growth factor-beta signaling pathway
por: Seo, Hye-Young, et al.
Publicado: (2017)

Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice
por: Kim, Jin Hyun, et al.
Publicado: (2020)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2021)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
por: Gu, Namyi, et al.
Publicado: (2014)

The Effect of Compression Pressure on the First Layer Surface Roughness and Delamination of Metformin and Evogliptin Bilayer and Trilayer Tablets
por: Kim, Sun Ho, et al.
Publicado: (2023)

Src Inhibition Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation and Decreasing Connective Tissue Growth Factor
por: Seo, Hye-Young, et al.
Publicado: (2020)

Kahweol Induces Apoptosis in Hepatocellular Carcinoma Cells by Inhibiting the Src/mTOR/STAT3 Signaling Pathway
por: Seo, Hye-Young, et al.
Publicado: (2021)

In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations
por: Jeong, Hyeon-Uk, et al.
Publicado: (2015)

Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
por: Choi, Bongkun, et al.
Publicado: (2021)

Clusterin Attenuates Hepatic Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Downregulating the Smad3 Signaling Pathway
por: Seo, Hye-Young, et al.
Publicado: (2019)

The quality of non-alcoholic fatty liver disease information resources for patients on the internet in Korea
por: So, In Tae, et al.
Publicado: (2021)

Huge Hepatocellular Carcinoma Exhibiting a Complete Response after Stereotactic Body Radiation Therapy
por: Shin, Kyung In, et al.
Publicado: (2020)

Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation
por: Seo, Songyi, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise
por: Park, Juri, et al.
Publicado: (2017)

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Kim, Mi-Jin, et al.
Publicado: (2020)

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study
por: Wang, Zheng, et al.
Publicado: (2019)

Application of Mesenchymal Stem Cells in Inflammatory and Fibrotic Diseases
por: Ryu, Jae-Sung, et al.
Publicado: (2020)

Effects of the Combination of Evogliptin and Leucine on Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice
por: Shin, Chang Yell, et al.
Publicado: (2021)

Gamma Linolenic Acid Exerts Anti-Inflammatory and Anti-Fibrotic Effects in Diabetic Nephropathy
por: Kim, Do-Hee, et al.
Publicado: (2012)

Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
por: Hong, Sang‐Mo, et al.
Publicado: (2017)

High Sodium Intake, as Assessed by Urinary Sodium Excretion, Is Associated with Nonalcoholic Fatty Liver Disease or Sarcopenia
por: Han, Eugene, et al.
Publicado: (2023)

Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice
por: Pham, Trong Kha, et al.
Publicado: (2023)

A new FGFR inhibitor disrupts the TGF‐β1‐induced fibrotic process
por: Kim, Mi‐Hyoung, et al.
Publicado: (2019)

The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis
por: Tang, Qizhi, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice
por: Chae, Yu-Na, et al.
Publicado: (2015)

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
por: Yoon, Hyunyee, et al.
Publicado: (2021)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2022)

Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study
por: Cercato, Cintia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fvdlkn67ivc9lvi2fofuf6flvt